Exosome-Based Detection for Pancreatic Cancer
(PCDC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to find a better way to detect pancreatic ductal adenocarcinoma (a type of pancreatic cancer) early and without invasive procedures. Researchers are testing a new method that identifies specific tiny particles in the blood called exosomes, which carry genetic information like miRNA (molecules that help control gene activity). The trial includes two groups: individuals with this type of pancreatic cancer and those without it. Suitable participants are those already diagnosed with pancreatic ductal adenocarcinoma or those confirmed through medical tests to be free of the disease. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to early, non-invasive detection methods for pancreatic cancer.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this exosome-based miRNA signature is safe for early detection of pancreatic ductal adenocarcinoma?
Research has shown that exosome-based tests, such as PANXEON, are generally safe for people. Exosomes, tiny particles in body fluids, enable a noninvasive method for cancer detection, eliminating the need for surgery or needles to collect a sample.
In past studies, patients reported no serious side effects from similar exosome-based tests. These tests aim to detect pancreatic cancer early by accurately identifying signs without causing harm. As a diagnostic tool rather than a drug, PANXEON presents much lower risks compared to treatments like chemotherapy or surgery.
Overall, the PANXEON test has been well-tolerated in research settings, making it a promising option for early detection of pancreatic cancer.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to enhance how we detect pancreatic ductal adenocarcinoma, a particularly aggressive form of cancer. Unlike traditional methods that rely heavily on imaging and invasive biopsies, this trial explores a more refined approach to differentiate between individuals with and without the disease. By focusing on new detection techniques, the trial hopes to improve early diagnosis, which is crucial for better treatment outcomes. This innovative approach could lead to more personalized and less invasive diagnostic options, potentially transforming how pancreatic cancer is detected and managed in the future.
What evidence suggests that the PANXEON test is effective for early detection of pancreatic cancer?
Research has shown that tests using exosomes, tiny particles released by cells, could significantly advance early detection of pancreatic cancer. A large study found a specific pattern of miRNA, a type of genetic material, in these exosomes that can help identify this cancer sooner. The PANcreatic cancer Exosome Early detectiON (PANXEON) test will be used in this trial to differentiate between individuals with and without pancreatic ductal adenocarcinoma. These exosomes have shown promise in distinguishing between those with and without the disease. Another study highlighted certain proteins in exosomes, such as ALPPL2 and THBS2, as possible early indicators of this cancer. These discoveries suggest that the PANXEON test might offer a new, noninvasive method for earlier detection of pancreatic cancer, which is crucial for improving treatment outcomes.16789
Who Is on the Research Team?
Ajay Goel, PhD
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Training
Participants' miRNA signatures are analyzed to train the detection model
Validation
The trained model is validated on a separate cohort to confirm its effectiveness
Follow-up
Participants are monitored for safety and effectiveness after the study
What Are the Treatments Tested in This Trial?
Interventions
- PANcreatic cancer Exosome Early detectiON (PANXEON)
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Individuals diagnosed with pancreatic ductal adenocarcinoma
Individuals diagnosed with pancreatic ductal adenocarcinoma
Individuals without pancreatic ductal adenocarcinoma
Individuals without pancreatic ductal adenocarcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
Citations
NCT06388967 | Pancreatic Cancer Detection Consortium
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma. Detailed ...
An exosome-based transcriptomic signature for ...
An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study.
Exosomal ALPPL2 and THBS2 as biomarkers for early ...
Lack of reliable biomarkers for early detection and monitoring contributes to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC), ...
Dr Goel on the Future of an Exosome-Based Liquid Biopsy ...
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of pancreatic cancers and carries a 5-year overall survival (OS) rate of ...
Exosome-based advances in pancreatic cancer
MSC-derived exosomes enhance therapeutic delivery in pancreatic cancer. They modulate the tumor microenvironment, inhibiting tumor progression.
6.
clinicaltrials.gov
clinicaltrials.gov/study/NCT06388967?cond=pancreatic%20cancer%20detection&term=panxeon&rank=1NCT06388967 | Pancreatic Cancer Detection Consortium
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma. Detailed ...
Pancreatic Cancer Detection Consortium
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Exosome applications for the diagnosis and treatment of ...
An Exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study.
Multifunctional exosome-driven pancreatic cancer ...
An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.